Clinical Trial Results:
A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg tablets) in patients with painful knee osteoarthritis, Kellgren-Lawrence grade 3 by X-ray
Summary
|
|
EudraCT number |
2004-001754-92 |
Trial protocol |
DE IT |
Global completion date |
27 Jul 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Jan 2017
|
First version publication date |
06 Jan 2017
|
Other versions |
|
Summary report(s) |
2004-001754-92 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.